Immatics NV

IMTX

Healthcare|Biotechnology|Germany

$9.68

-0.28 (-2.81%)

Tangible Book

$3.84

About

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Stock Price

+61.3%(1Y)

Pipeline Summary

18 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 11Terminated: 2Recruiting: 4Active: 1

Active Trials (5)

ACTengine® IMA203 Combined With mRNA-4203

NCT06946225Cutaneous Melanoma

Phase 1Recruiting

Enrollment: 15 participants

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT03686124Refractory Cancer

Phase 1Phase 2Recruiting

Enrollment: 375 participants

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

NCT05359445Refractory Cancer

Phase 1Active

Enrollment: 95 participants

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126Melanoma, Cutaneous Malignant

Phase 3Recruiting

Enrollment: 360 participants

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

NCT05958121Refractory Cancer

Phase 1Phase 2Recruiting

Enrollment: 400 participants

BioScore

4.9/10

Cautious

Ownership

Data last updated: Jul 13, 2026, 12:46 PM